Autolus Therapeutics plc ADR

AUTLNASDAQ · USD
1.06USD0.00 (-2.76%)
325

Autolus Therapeutics plc ADR (AUTL) Implied Volatility Current

AUTL's 30 day implied volatility is 498.56%, with an IV Rank of 99.60%. This is a high IV Rank versus the past year, meaning Autolus Therapeutics plc ADR options are relatively expensive and currently favor sellers. AUTL's 30 day historical volatility sits at 58.00%, which means implied volatility is running 440.56 points above historical volatility, as of Nov 18, 2026.

Read more

Tracking AUTL implied volatility helps you spot when Autolus Therapeutics plc ADR options are historically cheap or expensive, and where the best trades are hiding. When AUTL IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor AUTL implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking AUTL IV rank helps you see whether AUTL's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Implied Volatility

IV Rank
99.60%IV Rank
High

IV is highly elevated. Premiums are expensive, strongly favoring sellers.

Implied Volatility (30d)498.56%

IV Rank99.60%

Historical Volatility (30d)58.00%

IV Minus HV+440.56%

As of Nov 18, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →